EHA 2025: Improved Outcomes in High-Risk MCL with Acalabrutinib Combination Therapy 

A post hoc analysis presented at EHA 2025 by Professor Martin Dreyling reinforces the clinical benefit of acalabrutinib in combination with bendamustine-rituximab for patients with high-risk mantle cell lymphoma and supports the combination as a promising first-line option for elderly patients with high-risk MCL.